Similar Items: Verification and correlation of JAK2 p.V617F diagnostic assays and haematologic implications of JAK2 p.Val617Phe allele burden in Myeloproliferative neoplasm patients at Tygerberg Hospital
- Implementation of the JAK2V617F mutation analysis in the pathway of suspected myeloproliferative neoplasms in Groote Schuur Hospital
- Detection of the Janus kinase 2 V617F mutation using molecular methods
- The role of African horse sickness virus non-structural protein NS4 in virulence and host immunity
- Cytotoxic Activity of Salvia Officinalis Extract Mediated by the Inhibition of JAK2 in Breast Cancer
- EXPRESSION OF CONCERN: A Newly Identified 45‐kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance
- Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
Author: Swanepoel, Carmen
- Design, optimisation and validation of molecular diagnostic assays for BRAF p.Val600Glu and associated genetic factors within hairy cell leukemia (HCL) and HCL-like entities at Tygerberg Hospital, South Africa
- Screening and characterisation of BCR::ABL1 kinase domain mutations in chronic myeloid leukaemia participants at Tygerberg Hospital, South Africa
- Verification and correlation of JAK2 p.V617F diagnostic assays and haematologic implications of JAK2 p.Val617Phe allele burden in Myeloproliferative neoplasm patients at Tygerberg Hospital
- Design and validation of molecular diagnostic assays for key prognostic biomarkers, FLT3-ITD, NPM1, DNMT3A and CEBPA in cytogenetically normal aml patients at Tygerberg Hospital, South Africa
- Imatinib resistance : the role of pharmacogenetic variability in a South African chronic myeloid leukemia cohort
- Evaluating the role of long-term urine bio-banking on the stability of urine bio-markers in the diagnosis of pre-eclampsia